Compare Neurocrine Biosciences Inc (NBIX) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while iShares Broad USD Investment Grade Corporate Bond trades at $49.89. The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals.
| NBIX | USIG | |
|---|---|---|
Market Cap | $15.77B | — |
Sector | Health | Fixed Income |
52-Week High | $185.50 | $52.69 |
52-Week Low | $123.10 | $49.89 |
Enterprise Value | $15.78B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
USIG trades at $49.96, down 0.08% on the day, with technical indicators showing a bearish trend. Recent corporate actions include scheduled dividend payments in 2026. Institutional interest is evident from new stakes by Blue Edge Capital LLC and increased holdings by Bank of New York Mellon Corp, as reported by Defense World and Business Wire in July and August 2026.
The outlook remains cautious due to bearish technical signals and lack of recent fundamental data. Investment opportunities hinge on future financial disclosures and institutional support, while risks include market volatility and reliance on upcoming earnings for valuation clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
